Sanofi and Regeneron will simplify their antibody collaboration for Kevzara (sarilumab) and Praluent (alirocumab) by restructuring into a royalty-based agreement.
Under the proposed restructuring, Sanofi is expected to gain sole global rights to Kevzara and sole ex-U.S. rights to Praluent. Regeneron is expected to gain sole U.S. rights to Praluent.
Under the proposed terms of the agreement, each party will be solely responsible for funding development and commercialization expenses in their respective territories. These changes are expected to increase efficiency and streamline operations for the products.
The existing collaboration relating to Dupixent (dupilumab), which recently reached $633 million in global sales, will remain unchanged following the restructuring. Completion of the proposed arrangement is expected to be finalized in the first quarter of 2020.
Read the full Regeneron release